Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.

ABSTRACT:

Background

We have verified a mass spectrometry (MS)-based targeted proteomics signature for the detection of malignant pleural mesothelioma (MPM) from the blood.

Methods

A seven-peptide biomarker MPM signature by targeted proteomics in serum was identified in a previous independent study. Here, we have verified the predictive accuracy of a reduced version of that signature, now composed of six-peptide biomarkers. We have applied liquid chromatography-selected reaction monitoring (LC-SRM), also known as multiple-reaction monitoring (MRM), for the investigation of 402 serum samples from 213 patients with MPM and 189 cancer-free asbestos-exposed donors from the United States, Australia, and Europe.

Results

Each of the biomarkers composing the signature was independently

SUBMITTER: Cerciello F 

PROVIDER: S-EPMC7541795 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature